GIC makes another bet on Chinese pharma

Singapore’s state fund leads $85 million funding for Harbour BioMed, marking its third investment in the Chinese pharmaceutical space in four months.

Singapore’s sovereign wealth fund GIC Private has led an $85 million financing round for Chinese pharmaceutical startup Harbour BioMed, extending its long streak of private equity investment in China so far this year.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media